US › Healthcare

Cabaletta Bio Inc (CABA)

US · Healthcare · Biotechnology

$1.30+1.56%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-51.0M

EPS

$-0.34

EPS estimate

$-0.37

EPS came in at -0.34 against a street estimate of -0.37 — a beat of 8.1%.

Key statistics

Market cap

$217.0M

Forward P/E

0.0

P/B

1.15

Book value

$1.11

EPS (TTM)

$-1.33

52-week high

$4.23

52-week low

$1.18

50-day MA

$2.20

200-day MA

$2.85

Beta

3.54

Analyst view

Analysts rate Cabaletta Bio Inc a strong buy (8 buy, 2 hold, 0 sell out of 10) with an average price target of $13.25.

Shareholding

Insiders

0.97%

Institutions

95.37%

Largest institutional holders

Fund	Stake
Jennison Associates LLC	11.82%
T. Rowe Price Investment Management,Inc.	11.13%
Bain Capital Life Sciences Investors, LLC	10.17%
BlackRock Inc	6.34%
Adage Capital Partners Gp LLC	5.41%
State Street Corp	4.62%
Vanguard Capital Management, LLC	4.26%
Cormorant Asset Management, LLC	2.95%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cabaletta Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.